Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Microbiol Rev. 2009 Jan;22(1):76-98, Table of Contents. doi: 10.1128/CMR.00034-08.

Immunobiology of human cytomegalovirus: from bench to bedside.

Author information

  • 1Division of Immunology, Tumour Immunology Laboratory, Australian Centre for Vaccine Development, Queensland Institute of Medical Research, Brisbane, Queensland, Australia.

Abstract

SUMMARY:

Following primary infection, human cytomegalovirus (HCMV) establishes lifelong latency and periodically reactivates without causing symptoms in healthy individuals. In the absence of an adequate host-derived immune response, this fine balance of permitting viral reactivation without causing pathogenesis is disrupted, and HCMV can subsequently cause invasive disease and an array of damaging indirect immunological effects. Over the last decade, our knowledge of the immune response to HCMV infection in healthy virus carriers and diseased individuals has allowed us to translate these findings to develop better diagnostic tools and therapeutic strategies. The application of these emerging technologies in the clinical setting is likely to provide opportunities for better management of patients with HCMV-associated diseases.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk